Want to see LUCD full AI Analyst Report?
Total Valuation
Lucid Diagnostics has a market cap or net worth of $201.08M. The enterprise value is $99.46M.
Market Cap$201.08M
Enterprise Value$99.46M
Share Statistics
Lucid Diagnostics has 203,066,790 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding203,066,790
Owned by Insiders5.36%
Owned by Institutions0.03%
Financial Efficiency
Lucid Diagnostics’s return on equity (ROE) is -5.30 and return on invested capital (ROIC) is -135.05%.
Return on Equity (ROE)-5.30
Return on Assets (ROA)-1.43
Return on Invested Capital (ROIC)-135.05%
Return on Capital Employed (ROCE)-4.18
Revenue Per Employee65.36K
Profits Per Employee-805.69K
Employee Count72
Asset Turnover0.12
Inventory Turnover21.37
Valuation Ratios
The current PE Ratio of Lucid Diagnostics is ―. Lucid Diagnostics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio23.61
PB Ratio10.16
Price to Fair Value10.16
Price to FCF-2.39
Price to Operating Cash Flow-2.22
PEG Ratio0.05
Income Statement
In the last 12 months, Lucid Diagnostics had revenue of 4.71M and earned -58.01M in profits. Earnings per share was -0.69.
Revenue4.71M
Gross Profit-2.84M
Operating Income-49.64M
Pretax Income-58.01M
Net Income-58.01M
EBITDA-57.12M
Earnings Per Share (EPS)-0.69
Cash Flow
In the last 12 months, operating cash flow was -46.12M and capital expenditures -319.00K, giving a free cash flow of -46.44M billion.
Operating Cash Flow-46.12M
Free Cash Flow-46.44M
Free Cash Flow per Share-0.23
Dividends & Yields
Lucid Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.36
52-Week Price Change-12.28%
50-Day Moving Average1.03
200-Day Moving Average1.15
Relative Strength Index (RSI)45.93
Average Volume (3m)1.48M
Important Dates
Lucid Diagnostics upcoming earnings date is Aug 17, 2026, After Close (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Lucid Diagnostics as a current ratio of 1.31, with Debt / Equity ratio of 670.08%
Current Ratio1.31
Quick Ratio1.30
Debt to Market Cap0.22
Net Debt to EBITDA0.16
Interest Coverage Ratio-2.26K
Taxes
In the past 12 months, Lucid Diagnostics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Lucid Diagnostics EV to EBITDA ratio is -1.79, with an EV/FCF ratio of -2.20.
EV to Sales21.72
EV to EBITDA-1.79
EV to Free Cash Flow-2.20
EV to Operating Cash Flow-2.20
Balance Sheet
Lucid Diagnostics has $27.88M in cash and marketable securities with $26.80M in debt, giving a net cash position of $1.07M billion.
Cash & Marketable Securities$27.88M
Total Debt$26.80M
Net Cash$1.07M
Net Cash Per Share<$0.01
Tangible Book Value Per Share$0.10
Margins
Gross margin is -40.03%, with operating margin of -1054.82%, and net profit margin of -1232.68%.
Gross Margin-40.03%
Operating Margin-1054.82%
Pretax Margin-1232.68%
Net Profit Margin-1232.68%
EBITDA Margin-1213.68%
EBIT Margin-1232.21%
Analyst Forecast
The average price target for Lucid Diagnostics is $3.95, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$3.95
Price Target Upside223.77% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast23.03%
EPS Growth Forecast60.80%